Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Safety, Tolerability and Pharmacokinetics of Nivolumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors (CheckMate 077)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02593786
Recruitment Status : Active, not recruiting
First Posted : November 1, 2015
Last Update Posted : August 10, 2020
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
The purpose of this study is to determine whether nivolumab is safe and effective in the treatment of advanced or recurrent solid tumors in Chinese subjects.

Condition or disease Intervention/treatment Phase
Solid Tumors Drug: Nivolumab Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 56 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2, Open-Label Study of Nivolumab (BMS-936558) in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors (CheckMate 077: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 077)
Actual Study Start Date : December 25, 2015
Estimated Primary Completion Date : September 3, 2021
Estimated Study Completion Date : September 3, 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Nivolumab

Arm Intervention/treatment
Experimental: Nivolumab monotherapy
Nivolumab specified dose on specified days
Drug: Nivolumab
Experimental: Cohort Expansion
Nivolumab specified dose on specified days
Drug: Nivolumab



Primary Outcome Measures :
  1. Safety measured by number of subjects who experience AEs, SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations [ Time Frame: Up to 100 days after last dose of study drug ]
    Serious Adverse event (SAE), Adverse event (AE)

  2. Tolerability measured by number of subjects who experience AEs, SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations [ Time Frame: Up to 100 days after last dose of study drug ]

Secondary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: Up to 100 days after last dose of study drug ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

  • Chinese subjects with advanced or recurrent solid tumors

Exclusion Criteria:

  • Subjects with brain metastases are excluded unless clinically stable for more than 2 weeks at the time of enrollment as determined by the investigator
  • Subjects with carcinomatous meningitis are excluded

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02593786


Locations
Layout table for location information
China, Guangdong
Local Institution
Guangzhou, Guangdong, China, 510060
China, Zhejiang
Local Institution
Hangzhou, Zhejiang, China, 310016
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Study Director: Bristol Myers Squibb Bristol-Myers Squibb
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT02593786    
Other Study ID Numbers: CA209-077
First Posted: November 1, 2015    Key Record Dates
Last Update Posted: August 10, 2020
Last Verified: August 2020
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Nivolumab
Antineoplastic Agents, Immunological
Antineoplastic Agents